Division of Colorectal Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Ann Surg Oncol. 2020 Jul;27(7):2169-2176. doi: 10.1245/s10434-019-08155-4. Epub 2020 Jan 2.
Local excision (LE) has been proposed as an alternative to radical resection for early distal rectal cancer, for which the optimal oncologic treatment remains unclear.
The goal of this study was to compare the overall survival of rectal cancer patients with early distal tumors who underwent LE versus abdominoperineal resection (APR) using a large contemporary database.
The National Cancer Database (2004-2013) was used to identify patients with early T-stage rectal adenocarcinoma who underwent LE or APR. Patients were split into groups based on T stage and type of surgery (LE vs. APR). The primary outcome measure was overall survival. An adjusted Cox proportional hazards model was used to evaluate the impact of treatment strategy on survival.
Overall, there were 2084 patients with T1 tumors and 912 patients with T2 tumors. For patients with T1 disease, after adjusting for age, sex, income level, race, Charlson score, insurance payor, and tumor size, there was no significant difference in survival between the LE and APR groups (hazard ratio [HR] 0.89, 95% confidence interval [CI] 0.65-1.22; P = 0.49). For patients with T2 disease, after adjusting for age, Charlson score, and tumor size, there was no significant difference in survival between patients undergoing LE + chemoradiation therapy (CRT) and APR (HR 1.11, 95% CI 0.84-1.45; P = 0.47).
Patients with early distal rectal adenocarcinoma who underwent LE had similar survival to patients who underwent APR. LE is an acceptable oncologic treatment strategy for patients with T1 rectal cancers, and LE with CRT is an acceptable oncologic treatment for patients with T2 distal rectal cancers.
局部切除术 (LE) 已被提议作为早期远端直肠癌的根治性切除术的替代方法,对于这种癌症的最佳肿瘤治疗方法仍不清楚。
本研究的目的是使用大型当代数据库比较接受 LE 与经腹会阴切除术 (APR) 的早期远端直肠肿瘤患者的总生存率。
国家癌症数据库 (2004-2013) 用于识别接受 LE 或 APR 的早期 T 期直肠腺癌患者。根据 T 分期和手术类型 (LE 与 APR) 将患者分为两组。主要观察指标是总生存率。采用调整后的 Cox 比例风险模型评估治疗策略对生存的影响。
总体而言,有 2084 例 T1 肿瘤患者和 912 例 T2 肿瘤患者。对于 T1 疾病患者,在调整年龄、性别、收入水平、种族、Charlson 评分、保险支付者和肿瘤大小后,LE 和 APR 组之间的生存无显著差异(风险比 [HR] 0.89,95%置信区间 [CI] 0.65-1.22;P=0.49)。对于 T2 疾病患者,在调整年龄、Charlson 评分和肿瘤大小后,接受 LE+放化疗与 APR 治疗的患者的生存无显著差异(HR 1.11,95%CI 0.84-1.45;P=0.47)。
接受 LE 的早期远端直肠腺癌患者的生存与接受 APR 的患者相似。LE 是 T1 直肠癌症患者可接受的肿瘤治疗策略,LE 联合 CRT 是 T2 远端直肠癌症患者可接受的肿瘤治疗策略。